As a result of AHA’s successful litigation to stop the Centers for Medicare & Medicaid Services’ unlawful 340B payment policy in calendar year 2022, Medicare Administrative Contractors will pay 340B hospitals Average Sales Price plus 6%, rather than ASP minus 22.5%, for all CY 2022 drug claims with modifier “JG,” the Center for Medicare and Medicaid Services confirmed for AHA yesterday. Judge Rudolph Contreras of the U.S. District Court for the District of Columbia on Sept. 18 ordered CMS to immediately halt its unlawful outpatient payment reimbursement for certain 340B hospitals. 

Affected 340B hospitals should reach out to their MAC if the contractor has not notified them about the adjustment to ensure eligible 2022 claims for drugs provided before Sept. 28 are adjusted. CMS will auto-process any claims after Sept. 28, as previously announced on its website.  

AHA called the clarification a significant victory for 340B hospitals subject to the outpatient prospective payment system cuts in CY 2022, which will help them to continue to serve their communities. 

Related News Articles

Headline
The AHA May 25 published a report on the 340B Drug Pricing Program, its history and value to hospitals and patients, and details on 340B contract pharmacy…
Headline
The House Energy and Commerce Subcommittee on Health May 17 considered a series of health care bills, including a number focused on provisions that would…
Headline
The AHA strongly opposes legislation that would lead to additional site-neutral payment cuts and threaten access to patient care, Ashley Thompson, AHA senior…
Headline
More than 1,000 executive leaders from the nation’s top hospitals and health systems convened at the 2023 AHA Annual Membership Meeting, April 23-25 in…
Headline
The AHA, joined by the Arkansas Hospital Association and 340B Health, late Friday filed an amicus brief in the U.S. Court of Appeals for the 8th Circuit…
Headline
The Pharmaceutical Research and Manufacturers of America’s new ASAP 340B coalition “is another misguided attempt by drug companies to dismantle the 340B Drug…